Publikationen

Seitz T, Hackl C, Freese K, Dietrich P, Mahli A, Thasler RM, Thasler WE, Lang SA, Bosserhoff AK, Hellerbrand C. Xanthohumol, a Prenylated Chalcone Derived from Hops, Inhibits Growth and Metastasis of Melanoma Cells. Cancers. 2021 Jan 29;13(3):511.

Jefremow A, Wiesmueller M, Rouse RA, Dietrich P, Kremer AE, Waldner MJ, Neurath MF, Siebler J. Beyond the border: The use of lenvatinib in advanced hepatocellular carcinoma after different treatment lines – a retrospective analysis. J. Physiol. Pharmacol. 2021 (in press).

Schierwagen R, Dietrich P, Klein S, Uschner FE, Ortiz C, Tyc O, Torres S, Hellerbrand C, Sauerbruch T, Trebicka J. β-Arrestin2 is increased in liver fibrosis in humans and rodents. Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27082-27084.

Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss MM, Heppt F, Meder C, Atreya R, Klenske E, Dietrich P, Abdullah A, Kliem T, Corte G, Morf H, Leppkes M, Kremer AE, Ramming A, Pachowsky M, Schuch F, Ronneberger M, Kleinert S, Maier C, Hueber AJ, Manger K, Manger B, Berking C, Tenbusch M, Überla K, Sticherling M, Neurath MF, Schett G. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun. 2020 Jul 24;11(1):3774.

Dietrich P, Wormser L, Fritz V, Seitz T, De Maria M, Schambony A, Kremer AE, Günther C, Itzel T, Thasler WE, Teufel A, Trebicka J, Hartmann A, Neurath MF, von Hörsten S, Bosserhoff A, Hellerbrand C. Molecular cross-talk between Y5-receptor and neuropeptide Y drives liver cancer. J Clin Invest. 2020 May 1;130(5):2509-2526.

Seitz T, Freese K, Dietrich P, Thasler WE, Bosserhoff A, Hellerbrand C. Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma. Sci Rep. 2020 Mar 11;10(1):4546.

Linck-Paulus L, Hellerbrand C, Bosserhoff AK, Dietrich P. Dissimilar Appearances Are Deceptive-Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma. Cells. 2020 Jan 2;9(1).

Koch A, Ebert EV, Seitz T, Dietrich P, Berneburg M, Bosserhoff A, Hellerbrand C. Characterization of glycolysis-related gene expression in malignant melanoma. Pathol Res Pract. 2020 Jan;216(1):152752.

Freese K, Seitz T, Dietrich P, Lee SML, Thasler WE, Bosserhoff A, Hellerbrand C. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro. Cancers. 2019 Oct 18;11(10).

Dietrich P, Gaza A, Wormser L, Fritz V, Hellerbrand C, Bosserhoff AK. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma. Neoplasia. 2019 Mar;21(3):257-268.

Mahli A, Seitz T, Beckröge T, Freese K, Thasler WE, Benkert M, Dietrich P, Weiskirchen R, Bosserhoff A, Hellerbrand C. Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro. Cells. 2019 May 15;8(5).

Dietrich P, Hellerbrand C, Bosserhoff A. The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression. Cancers. 2019 Mar 21;11(3).

Goeppert B, Truckenmueller F, Ori A, Fritz V, Albrecht T, Fraas A, Scherer D, Silos RG, Sticht C, Gretz N, Mehrabi A, Bewerunge-Hudler M, Pusch S, Bermejo JL, Dietrich P, Schirmacher P, Renner M, Roessler S. Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p. Sci Rep. 2019 Mar 18;9(1):4796.

Stieglitz D, Lamm S, Braig S, Feuerer L, Kuphal S, Dietrich P, Arndt S, Echtenacher B, Hellerbrand C, Karrer S, Bosserhoff AK. BMP6-induced modulation of the tumor micro-milieu. Oncogene. 2019 Jan;38(5):609-621.

Schmidt KM, Dietrich P, Hackl C, Guenzle J, Bronsert P, Wagner C, Fichtner-Feigl S, Schlitt HJ, Geissler EK, Hellerbrand C, Lang SA. Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis. Neoplasia. 2018 Dec;20(12):1198-1208.

Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Bosserhoff AK. MicroRNA-622 is a novel mediator of tumorigenicity in melanoma by targeting Kirsten rat sarcoma. Pigment Cell Melanoma Res. 2018 Sep;31(5):614-629.

Dietrich P, Koch A, Fritz V, Hartmann A, Bosserhoff AK, Hellerbrand C. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut. 2018 Jul;67(7):1328-1341.

Dietrich P, Bosserhoff AK. Melanoma sponge on pigmentation gene to reduce tumour-suppressive microRNAs. Pigment Cell Melanoma Res. 2018 May;31(3):350-351.

Mahli A, Saugspier M, Koch A, Sommer J, Dietrich P, Lee S, Thasler R, Schulze-Luehrmann J, Luehrmann A, Thasler WE, Müller M, Bosserhoff A, Hellerbrand C. ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis. Gut. 2018 Apr;67(4):746-756.

Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Bosserhoff AK. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition. Oncogene. 2018 Feb 15;37(7):897-911.

Dietrich P, Freese K, Mahli A, Thasler WE, Hellerbrand C, Bosserhoff AK. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option. Oncotarget. 2017 Dec 11;9(3):3605-3618.

Dietrich P, Bosserhoff AK. DNMT targets MiRacle torching TORCh. Pigment Cell Melanoma Res. 2016;29(4): 399-401

Delic S, Thuy A, Schulze M, Proescholdt MA, Dietrich P, Bosserhoff AK, Riemenschneider MJ. Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority Targets Genes Chromosomes Cancer. 2015;54(7): 433-443 

Ruedel A* and Dietrich P*, Schubert T, Hofmeister S, Hellerbrand C, Bosserhoff AK (*contributed equally). Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts. Int J Clin Exp Pathol. 2015;8(5): 4953-62

Hartl J, Dietrich P, Moleda L, Müller-Schilling M, Wiest R. Neuropeptide Y restores non-receptor-mediated vasoconstrictive action in superior mesenteric arteries in portal hypertension. Liver Int. 2015;35(12): 2556-63

Dietrich P, Bosserhoff AK. Modifying microRNAs–another piece of the melanoma puzzle. Pigment Cell Melanoma Res. 2015;28(5): 488-9

Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4): 637-53

Dietrich P, Moleda L, Kees F, Müller M, Straub RH, Hellerbrand C, Wiest R. Dysbalance in sympathetic neurotransmitter release and action in cirrhotic rats: Impact of exogenous neuropeptide Y. J Hepatol. 2013 Feb;58(2):254-61

Dietrich P, Hellerbrand C. Alkoholische und nichtalkoholische Steatohepatitis – Gemeinsamkeiten und Interaktion von pathophysiologischen Mechanismen. Verdauungskrankheiten 2012; Jahrgang 30, Nr. 5/2012, S. 233-2

Moleda L, Trebicka J, Dietrich P, Gäbele E, Hellerbrand C, Straub RH, Sauerbruch T, Schoelmerich J, Wiest R. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. Gut 2011; Aug;60(8):1122-32